- Home
- MDCX vs QNCX Comparison
MDCX vs QNCX Comparison
Compare MDCX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | QNCX |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.5M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MDCX | QNCX |
|---|---|---|
| Price | $0.15 | $30.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 15.4K |
| Earning Date | 05-11-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.08 |
| 52 Week High | $2.78 | $35.41 |
Technical Indicators
Market Signals| Indicator | MDCX | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 29.90 | 53.67 |
| Support Level | $0.15 | $29.95 |
| Resistance Level | $0.19 | $35.38 |
| Average True Range (ATR) | 0.01 | 2.10 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 14.70 | 65.49 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.